The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castrate resistant prostate cancer who have progressed on an androgen receptor targeting agent.
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AVEO; Bayer; bristol -Myers Squibb; EMD Serono; Exelixis; Hinova Pharmaceuticals; Infinity Pharmaceuticals; Janssen Oncology; Merck; Myovant Sciences; Myovant Sciences; Pfizer; Propella Therapeutics; Seagen; Veru; Veru
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Seagen (Inst)
 
Franklin Chu
Research Funding - Veru (Inst)
 
David J Cahn
Research Funding - Veru
 
Robert H. Getzenberg
Employment - Veru; Veru
Leadership - Veru
Stock and Other Ownership Interests - Veru; Veru
Consulting or Advisory Role - Veru
 
Domingo Rodriguez
Employment - Veru
Stock and Other Ownership Interests - Veru
 
K. Gary Barnette
Employment - Veru
Leadership - Veru
Stock and Other Ownership Interests - Veru
 
Mitchell S. Steiner
Employment - Veru
Leadership - Veru
Stock and Other Ownership Interests - Veru
 
Daniel R. Saltzstein
Consulting or Advisory Role - Veru
Research Funding - Veru (Inst)
 
Ronald F. Tutrone
Employment - Chesapeake Urology
Stock and Other Ownership Interests - Myovant Sciences; Novartis; Nymox; Veru
Consulting or Advisory Role - Exosome Diagnostics; Myovant Sciences; Nymox
Speakers' Bureau - Exosome Diagnostics; Medivation/Astellas; Pfizer
Research Funding - Advantagene (Inst); Advaxis (Inst); Bayer (Inst); Exosome Diagnostics (Inst); Genomic Health (Inst); Janssen Oncology (Inst); MDxHealth (Inst); Medivation/Astellas (Inst); Merck (Inst); Neotract (Inst); Nymox (Inst); OncoCellMDx (Inst); OncoCellMDx (Inst)
 
Neal D. Shore
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Propella Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Tolmar; Urogen pharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; Clovis Oncology; Dendreon; Exact Imaging; Ferring; Foundation Medicine; InVitae; Janssen; MDxHealth; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pfizer; Sanofi; Sesen Bio; Tolmar